Navigation Links
Genomic tumor testing to match lung cancer patients with targeted drugs transforms care
Date:5/20/2014

NEW YORK, May 20, 2014 New data from a study led by Memorial Sloan Kettering physicians that used targeted therapy for patients with the most common type of lung cancer has helped transform treatment for the disease.

The Lung Cancer Mutation Consortium (LCMC), composed of a group of 14 US hospitals, incorporated tumor genotyping into therapeutic decision-making for patients with lung adenocarcinomas. An oncogenic driver was detected in 64 percent of tumors from patients in this study. Oncogenes, when activated by genetic mutations, can turn normal cells cancerous. Data from this study that will be published in the May 20 issue of the Journal of the American Medical Association shows that survival may be improved when drugs matched to the oncogenic drivers identified through this program are given to patients.

"This has transformed the way we treat people with lung cancers," said lead co-author Mark G. Kris, MD, the Ruane Chair in Thoracic Oncology at Memorial Sloan Kettering. "It used to be that when lung cancers were diagnosed solely by a visual microscopic examination of tumor tissues by a pathologist, every patient received the same intravenous chemotherapy. But now, we are personalizing the care of these individuals by finding the genetic alterations in the tumor tissues that drive their cancers and giving medicines that specifically counteract the cancerous effects of those genes."

Dr. Kris and colleagues used multiplex genetic testing to analyze DNA from tumor tissues and perform other techniques to detect the presence of ten driver oncogenes in more than 1,000 patients from 14 different hospitals across the United States. Patients with oncogenic drivers who received targeted drug treatment had a median survival of about 3.5 years; patients with oncogenic drivers who did not receive targeted therapies had a median survival of about 2.4 years; and patients with no identified oncogenic driver had a median survival of 2.1 y
'/>"/>

Contact: Melissa Morgenweck
morgenwm@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Following the genomic pathways to stop the spread of cancer
2. Genomic study of rare childrens cancer yields possible prognostic tool
3. Mayo, UCSF team discovers genomic variant that increases risk of brain tumors
4. Study identifies genes associated with genomic expansions that cause disease
5. $8.9 million NIH grant to study genomic link to premature heart disease
6. Edith Sanford Breast Cancer Foundation and TSRI partner in genomic breast cancer research
7. Molecular Genetics & Genomic Medicine: New open access journal launched by Wiley
8. Ontario Genomics Institute invests in stem cell technology at Tissue Regenerative Therapeutics
9. Study shows large-scale genomic testing feasible, impacts therapy
10. Stanford/Yale study gives insight into subtle genomic differences among our own cells
11. NIH grant moves pathologists to the forefront of genomic medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Los Angeles, California (PRWEB) October 22, 2014 ... Recovery 2.0: Move Beyond Addiction and Upgrade Your Life (Paperback; ... the field of Yoga & Recovery. This book is ... and thrive in a life of recovery. , Recovery ... of the 12 Steps; Recovery 2.0 is a guide for ...
(Date:10/22/2014)... Best Cheap Hosting USA is among ... site has recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) ... from around the world. , “iPower is one of ... is providing various kinds of useful products for new ... offering excellent customer service and a number of features ...
(Date:10/22/2014)... Although there are only 24 hours in a day, ... have trouble finding time within their busy schedules for exercise and ... of time to get in shape. Here are five ways you ... , Change Up Your Commute , Consider riding a bike ... exercise into your daily routine. If you must use your car ...
(Date:10/22/2014)... WALTHAM, MA (PRWEB) October 22, 2014 ... developing new solutions for the treatment of bacterial infections, ... J. Sinskey has joined its board of directors. ... Microbiology and Engineering Systems at The Massachusetts Institute of ... the MIT faculty since 1968. Dr. Sinskey also holds ...
(Date:10/22/2014)... -- Two sisters in high school have developed ways ... Medha Krishen use electronic stethoscopes, which electronically amplify body ... patterns or heartbeats. Ilina, a senior at Port ... a way to detect early lung damage in people ... Ilina recorded one breath cycle each from 16 smokers, ...
Breaking Medicine News(10 mins):Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2
... Surgeon, went ahead and purchased a medical equipment from ... permission// from the hospital authorities. Apparently, he had already ... at James Paget Hospital, Gorleston, Norfolk. A retractor, which ... placed the huge order. ,Since a retractor ...
... public demand for transparency in clinical trials involving humans, ... firms to register all such studies and include details ... ,'Registration of all clinical trials and full disclosure ... fundamental to ensuring transparency in medical research and fulfilling ...
... sum of Rs 749 crore would be spent in Haryana ... 2010 in order to reduce infant mortality rate// in the ... ,Addressing a Nav Nirman Rally organised by President of All ... here, Hooda said emphasis has been laid on improving health ...
... to the recent study it is said that researchers are ... mental illness by DNA profiling//. They are going to develop ... such as schizophrenia and autism. The skin tests are to ... which opened near Inverness. ,By the end of ...
... new Health Minister of Northern Ireland, expressing his apology over ... has stated that women who had suffered distress and anxiety ... out the delay in the cancer diagnosis of six women ... increase in risk of dying from breast cancer attributable to ...
... the onslaught of Foot-and-mouth disease. The disease has not spared ... only a small portion of the cattle// and pigs are ... and not as dangerous as avian flu," said Vu Ngoc ... in Hanoi. "There have not been a big number of ...
Cached Medicine News:Health News:Minster Apologizes To Women Involved In Breast Cancer Screening Scandal 2
(Date:10/20/2014)... 20, 2014  ResMed (NYSE: RMD ... Data Exchange program, a comprehensive suite of software ... and other health care providers. ... critical patient information. It integrates valuable sleep and ... patient management platforms with customers, in-house or third-party ...
(Date:10/20/2014)... --  BioNano Genomics announced today achievement of a major ... data at 30X depth, sufficient for a genome map, in ... established and demonstrated for the IrysChip TM V2, the ... and will be rolled out to BioNano,s collaborators and customers ... advancement at the American Society for Human Genetics (ASHG) ...
(Date:10/20/2014)... 2014   Taiho Oncology, Inc. , a ... Japan ), announced that the U.S. Food ... for TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), ... the treatment of refractory metastatic colorectal cancer (mCRC), ... NDA submission to the FDA. According to the ...
Breaking Medicine Technology:ResMed Launches ResMed Data Exchange 2BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 4
... for the most common, pathogens, including ... Oct. 26 Arpida (SWX:,ARPN) today presented ... III,clinical trials at the 48th Interscience Conference ... of America (IDSA) 46th,annual meeting in Washington, ...
... 26 Sequoia Pharmaceuticals presented,positive results today from ... inhibitor (PI). One study based on an in ... SPI-256 with HIV protease,provides a rationale for its ... second study conducted in healthy volunteers demonstrates,that SPI-256 ...
Cached Medicine Technology:Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 2Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 3Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 4Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 5Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 6Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 7Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor 2Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor 3Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor 4
... Avaulta™ BioSynthetic Mesh is ... coated in the central ... hydrophilic film of porcine ... of the Avaulta™ BioSynthetic ...
Comprised of a monofilament polypropylene mesh coated with hydrophilic porcine collagen, Pelvitex™ mesh is clinically proven coating to enhance the healing process, along with the strength and d...
... is a soft monofilament ... be used for a ... procedures, including cystocele, rectocele, ... yet strong, POPmeshs flexibility ...
... Hydrix XM is a ... pericardium, a material known for ... sourcing and manufacturing procedures ensure ... safety. Caldera's patented processing enhances ...
Medicine Products: